A predominant enhancer co-amplified with the SOX2 oncogene is necessary and sufficient for its expression in squamous cancer

Yanli Liu(National Medical Products Administration), Xiaoyang Zhang(University of Utah), Andrew D. Cherniack(Broad Institute), Zhong Wu(Nanfang Hospital), Jason Gertz(University of Utah), Swneke D. Bailey(McGill University Health Centre), Xiaojun Yang(Northwest A&F University), Xingdong Chen(Fudan University), Estrella Aguilera-Jimenez(Huntsman Cancer Institute), Jin Zhou(The University of Texas Southwestern Medical Center), Dinesh K. A. Ramadurai(University of Utah), Katherine E. Varley(University of Utah), Alison M. Taylor(Broad Institute), Adam J. Bass(Dana-Farber Cancer Institute), Katelyn L. Mortenson(University of Utah), Yifei Yan(McGill University Health Centre), Peter S. Choi(Children's Hospital of Philadelphia)
Nature Communications
December 8, 2021
Cited by 50


Related Papers